17 apr: FOCUS: Food Processors To Benefit From Cheaper Grain Prices
17 apr: UPDATE: Marathon Oil: Angola's Block 31 To Start Product..
17-04-2012 21:04:00

2nd UPDATE:Top Court Sides With Generic Drug Makers In Tactics Case

Relateret indhold
14:52 - 
Novo/dir: Vi tror stadig på en løsning i Tyskland
13:47 - 
Novo: Tyske myndigheder ser ikke fordele ved Tresiba - ..
31 jul - 
Torsdagens aktier: Bredt fald anført af Pandora og Carl..
Relateret debat
15:43 - 
Kære læser. Det er i strid med lov om ophavsret at kopi..
14:49 - 
Fik den fanget i ca 249,3, så det ser da ok ud :)
13:05 - 
Som regel har jeg kontanter stående eller ogs&ari..

--Justices give generics new legal tool against brand rivals

--Sun unit wins case, calls ruling important for generic drug makers

--Case involved Novo Nordisk patent for diabetes drug Prandin

(Updates with comment from Novo in 12th paragraph, additional background.)

By Brent Kendall

Of DOW JONES NEWSWIRES

WASHINGTON -(Dow Jones)- The U.S. Supreme Court handed a victory to generic drug companies Tuesday, ruling they can file certain legal counterclaims against brand-drug companies in an effort to get their cheaper copycat medicines on the market.

The court, in an opinion written by Justice Elena Kagan, ruled unanimously that generic drug makers should be allowed to challenge the way brand-name manufacturers describe their patents to the Food and Drug Administration.

The decision overturned an appeals court ruling that said generic makers can't bring those legal claims against brand rivals.

The generics argued that their brand rivals, if left unchecked, can describe their patents broadly in FDA submissions as a way to shut out possible generic competition, even for unpatented uses of a drug. The Obama administration supported those arguments.

Brand drug companies said allowing the counterclaims could lead to costly litigation and undermine patent protection for innovative drugs that are costly to develop.

The controversy arises when the FDA considers a drug maker's application to market a generic drug. As part of that process, the agency considers whether the proposed generic will infringe a branded drug's patents. To determine infringement, the FDA relies on use codes submitted by brand companies that describe the scope of their patents. The agency does not independently verify the accuracy of companies' patent submissions.

As Kagan noted, "the breadth of the use code may make the difference between approval and denial of a generic company's application."

At issue was an appeal by Caraco Pharmaceutical Laboratories, a unit of Sun Pharmaceutical Industries Ltd. (524715.BY), which is seeking to introduce a generic version of Novo Nordisk A/S's (NVO, NOVO-B.KO) diabetes drug Prandin.

One Novo Nordisk patent on the drug compound has expired, but the company holds a second patent, which doesn't expire until 2018, that involves the use of the drug in combination with another medicine.

The FDA has approved three uses for the drug. Caraco wants to introduce a generic version for the uses that aren't patented. The company said it couldn't do so because Novo Nordisk's description of its patent to the FDA was so broad that it foreclosed the agency from approving a generic version of the drug.

A Sun representative called Tuesday's ruling "a very important victory" for the company and the generic industry as a whole.

Novo said its FDA submission is correct. "We are confident that further proceedings will show Caraco's challenge to the use code narrative is meritless," James Shehan, general counsel of Novo's U.S. subsidiary, said in a statement.

In a related dispute, the two companies are fighting over the validity of the Novo patent, which a Michigan federal judge invalidated last year. That case is on appeal.

The case is Caraco Pharmaceutical Laboratories v. Novo Nordisk, 10-844.

-By Brent Kendall, Dow Jones Newswires; 202-862-9222; brent.kendall@dowjones.com

(END) Dow Jones Newswires

April 17, 2012 15:04 ET (19:04 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
12:27
NOVO-B
Edifier, at "samle op" i en aktie betyder ikke nødvendigvis, at man allerede "HAR aktier i firmaet",..
3
11:59
NOVO-B
Lige da du skrev det indlæg der, havde jeg lukket hoveddøren.   Der var altså meget fredeligt derude..
3
29 jul
NOVO-B
Hold den og læææænge.   BB
2
14:49
NOVO-B
Fik den fanget i ca 249,3, så det ser da ok ud :)
1
13:05
NOVO-B
Som regel har jeg kontanter stående eller også har jeg en aktiekredit hos Nordnet som jeg efterfølge..
1
12:05
NOVO-B
Som at tyvstjæle slik fra små børn..... sådan Markus 
1
12:01
NOVO-B
Ren gevinst hjemtagning, de aktier som er steget mest falder mest i dette tilbagefald, hvilket indik..
1
12:01
NOVO-B
Samler op i Novo nu.  Carl tør jeg ikke røre ved lige nu.  
1
11:49
NOVO-B
Ved ikke om du har prøvet at tænde for tv, læse nyheder, eller bare gå udenfor døren....    
1
29 jul
NOVO-B
Kender ikke Nordea. Hvis det er en Russisk bank, så er det ikke sikkert du kan.  
1

Novo: Tyske myndigheder ser ikke fordele ved Tresiba - NY

01-08-2014 13:47:20
Novo Nordisk er løbet ind i et nederlag i Tyskland.De tyske sundhedsmyndigheders rådgivende institut (IQWIG) er fredag kommet med en rapport, hvor det konkluder..

Mærsk: Vigtigt rateindeks vender kurven og stiger

01-08-2014 11:23:32
Det vigtige indeks over containerfragtrater, SCFI-indekset, har efter flere ugers fald vendt udviklingen og er steget 12,7 pct. i denne uge.Indekset, som viser ..

Genmab/Nordea: Arzerra-studier underbygger positiv holdning

01-08-2014 08:42:57
Genmab og partneren Glaxosmithkline offentliggjorde sent torsdag positive interimresultater med kræftmidlet Arzerra.Den foreløbige analyse, foretaget af en uafh..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/middag: Giftig cocktail trækker ned
2
Aktier/tendens: Faldene vil ebbe ud
3
Aktier/Nordnet: Private køber Pandora og Vestas
4
Europa/aktier: Adidas i største fald i 15 år
5
Torsdagens aktier: Bredt fald anført af Pandora og Carlsberg

Relaterede aktiekurser

Novo Nordisk B A/S 251,20 -2,6% Fald i aktiekurs
Novo-Nordisk A/S 45,24 -1,8% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
1. august 2014 15:55:17
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20140731.2 - EUROWEB7 - 2014-08-01 15:55:17 - 2014-08-01 15:55:17 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x